GT Biopharma Inc (GTBP)

[MagnumStocks]

DUKE's MASSIVE DD POST ON $GTBP or HOW TO GET RICH FIGHTING CANCER WITH GT BIOPHARMA


Ok. So if you are like me, even before you got through the first sentence, you were thinking, *yawn* another development phase BioPharma on the OTC that wants to beat cancer. Good luck to you, sincerely, but *yawn* not interested....



Yeah I understand your reaction. The big C word is not a new sexy problem, its a massive global epidemic that shows no signs of going away, and because of its very omnipresence it becomes easy to ignore. Each generation of brilliant scientists and doctors in the modern era promises to eradicate it, and each generation seems to make nowhere near as much progress as predicted . The overwhelming nature of the problem makes it easy to tune out the information.

BUT IM ASKING YOU TO STOP AND LISTEN THIS TIME. YOUR WALLET AND POSSIBLY YOUR FUTURE CANCER FREE SELF WILL THANK YOU LATER.

So let's do a Bad News, Good News, Better News sandwich ok? It'll help the medicine go down.


#1) The BAD News: The BAD news is cancer itself. There's no way to paint it pretty, society has got to stare this monster in the face if we are to make any progress. Consider...

Some Key Stats:

>>>>Most Common Forms of Cancer: Lung (1.69 million deaths), Liver (788 000 deaths), Colorectal (774 000 deaths), Stomach (754 000 deaths), Breast (571 000 deaths)
>>>>Cancer is the second leading cause of death globally, and was responsible for 8.8 million deaths in 2015. Globally, nearly 1 in 6 deaths is due to cancer.
>>>>Around one third of deaths from cancer are due to the 5 leading behavioral and dietary risks: high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, and alcohol use.
>>>>Late-stage presentation and inaccessible diagnosis and treatment are common. In 2017, only 26% of low-income countries reported having pathology services generally available in the public sector. More than 90% of high-income countries reported treatment services are available compared to less than 30% of low-income countries.
>>>>The Burden of Cancer in the United States. In 2018, an estimated 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease.

>>>>The economic impact of cancer is significant and is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion

DID YOU CATCH THAT? US$2.5 TRILLION! Put in perspective, thats about the same as the Gross Domestic Product of France!

So the bad news is actually really, really bad. Sorry to drop that on you. But bear with me for a moment and don't let the gravity of the scenario numb your thinking. Humanity is fighting back and actually we are making progress. As the ancient proverb goes, another word for "problem" is "opportunity". So you could call it a US$2.5 Trillion problem, but I choose to call it a US$2.5 Trillion opportunity.

Now hold on, before you go calling me a stone-cold mercenary, I just need to say yes, I am a trader, and yes, be it good, bad, or ugly I am convinced that free market capitalism is still the best motivation and milieu to motivate brilliant minds to work on difficult problems. I want to see humanity beat back this monster. Big problems with big human costs can plead for bigger monetary resources to fight back with. Bigger monetary resource and greater potential financial gain means the best, the brightest, and the most talented can be harnessed to win the battle. And that gives you a fighting chance to beat back the monster. And thats exactly whats going on with GT Biopharma. Its BIG news. IMHO it will bring BIG rewards to it's investors.



#2) THE GOOD NEWS: GT Biopharma is Fighting Back The Monster With Targeted Immuno Oncology

Said in another way:



AWESOME! ..... BUT WHAT THE DEUCES DOES THAT MEAN?!?

Glad you asked, because thats the same thing I said. I spent hours researching to try to wrap my head around it. I'm not going to give you all the technical jargon. There's plenty of that to dig into if you wish and there's plenty of ancillary details to keep you from seeing the forrest for the trees. Instead, I want to put the cookies on the bottom shelf. I want to zero in on the kernel at the core of GTBP's offering that makes it so brilliant, so revolutionary, so breath-takingly disruptive. I want you to grasp this one thing because if you do you'll see that $GTBP is the future of cancer treatment, and the only sensible position is to go LONG.
Ready? Here it is:

$GTBP FIGHTS CANCER WITH IMMUNO ONCOLGY. IMMUNO ONCOLOGY IS JUST A FIVE DOLLAR BIOMEDICAL WORD THAT MEANS DRUGS THAT SUPERCHARGE YOUR BODY'S OWN IMMUNE SYSTEM TO BEAT CANCER IN A TARGETED WAY.

So what? So everything. Consider the way that traditional chemotherapy works in cancer treatment. Measured doses of poison are given to the patient in hopes that it will kill the cancer without killing too many other necessary cells in the body... because... yeah, poison. Its like using RoundUp Herbicide to rid your flower garden of dandelions. Sure it kills the dandelions very well, but after application the hydrangeas and roses don't look so hot either.

This graphic really says it well:


Now don't get me wrong, we can thank God for chemotherapy because it has saved millions of lives. But if you are like me, and unfortunately you have had the sadness of watching loved ones battle cancer and go through chemo, then like me you witnessed scenes at times that left you asking if the cure was worse than the disease. Thats because chemotherapy is not targeted. It's like napalming the countryside in the hopes of getting the rebels. Yes, you may get the rebels, but you also do lots of collateral damage. Watching friends go through chemotherapy can be like watching them become walking collateral damage.

Immuno Oncology in contrast is targeted. Again this graphic is helpful:



Immuno Oncology is to cancer what smart bombs are to terrorists. It drops a Hellfire missile in the bad guy's lap without damaging the school next door. No collateral damage. The therapy can be calibrated to go only after the cancer cells or cancer stem cells, without damaging healthy cells. It can harness the bodies own "killer cells" to go after cancer cells and deliver deadly "payloads" to those malignant cells alone. This is a huge win not only against cancer, but for the dignity and quality of human life in the midst of medical treatment. It is not just a medicine, it is a victory for humanity.

But does it work?

Early stage testing has shown great promise. Working in collaboration with Dr. Jeffrey Miller of Univ. of Minnesota, recognized leader in immuno oncology, the drug OXS-1550 has been used successfully and seen patients suffering from lyphoma go into remission. One patient, a physics professor from the University of Minnesota, was suffering from late stage lymphoma and had endured many types of conventional and experimental therapies to no avail. Upon administration of two doses of OXS-1550, she was amazed not only to go into total remission, but to be able to do active things during treatment like jog around the lake, something that the side effects of non-targeted therapies like chemo or radiation would never have allowed.

IMMUNO ONCOLOGY THERAPY IS THE CUTTING EDGE FUTURE OF CANCER TREATMENT. THE GOAL IS TO REPLACE THE USD$100 BILLION CHEMOTHERAPY MARKET ENTIRELY ONE DAY.

OXS -1550 is currently in Phase 2 clinical testing and it is expected that results of the trials will be released around second half of 2018. IMHO the release of the trial results will likely lead to a large spike in PPS, and/or be the occasion for $GTBP to secure a new round of outside funding, all of which of course would be positive developments for shareholders.



OTHER CONSIDERATIONS IN NO PARTICULAR ORDER:
-OXS - 1550 is only one of the drugs that GTBP has in near-to-market testing. I highlight it here because its an illuminating case for the core technology and its the farthest along in development. I encourage you to read up on the companies other offerings as well.
-Endgame here would likely be a buyout by a larger BioPharma or the sale of the patents and intellectual property of GT Biopharma. Great for shareholders.
-The company anticipates an uplist to NASDAQ sometime in 2018. They have recently been adding executives to the team with the necessary skillset for such at transition. But more on that in a moment.


#3) THE BETTER NEWS: $GTBP's Executive Team Is Stacked With BioMedical Superstars. (Better not in the sense that point #3 tops point #2 per say, but in the sense that the whole picture is more attractive with the addition of #3 ;-D )

In recent months $GTBP has made huge strides in enhancing their executive team. This is a very important indicator for investors. The kind of leadership that has signed on board is the kind that has recent experience guiding clinical stage bioscience companies to MASSIVE profitability. The fact that they see similar potential in $GTBP is very telling. Because of the laws and SEC regulations surrounding forward looking statements, a clinical stage company like this can't come out and say "Hey, our offering is about to take off, and we are about to make boatloads of money." As investors we wish it could be that straightforward so we could have a clear BUY sign, but it just doesn't work that way. We have to look for other, less-direct signals, like the one we have here.

What you have is a bench of extremely succesful, wealthy, very highly qualified executives, who collectively have seen several bioscience companies grow through to the multi hundred million dollar exit strategy stage, that have recently signed on with GTBP and it's promising pipeline of drugs on the verge of clinical testing validation. Do you think executives of that calibre are just looking for some place to park? Or does their years of experience in biopharma tell them something about $GTBP that we ought to stop and take notice of?

Where Are Biotech Industry Vets Taking a Seat at the Table Right Now?
Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets

The answer of course is $GTBP. All indicators point to a major play developing.

-Be sure to check out their website: https://www.gtbiopharma.com/

-And the Company Overview from April 18th, 2018: https://d1io3yog0oux5.cloudfront.net/_deb8e2317d134ecfee9bb22f89a8c67b/gtbiopharma/db/184/467/pdf/GT+Bio+Company+Overview+April_18_2018.pdf

**Disclaimer: A financial advisor I am not. These are just my opinions. You need to do your own due dilligence. Mama says these kinds of stocks are very high risk and you could lose all your investment. You better listen to Mama.**